Males (n=48) | Females (n=37) | ||||
Measure | Effect of dexrazoxane on change at T1 (95% CI)* | P (dexrazoxane)† | Effect of dexrazoxane on change at T1 (95% CI)* | P (dexrazoxane)† | P (interaction)‡ |
Shortening fraction (%) | 0.5 (−2.4 to 3.4) | 0.73 | 5.7 (2.1 to 9.3) | 0.002 | 0.019 |
LVIDD (cm/BSA0.45) | 0.1 (−0.1 to 0.3) | 0.49 | −0.4 (−0.7 to −0.1) | 0.002 | 0.002 |
LVIDS (cm/BSA0.45) | −0.03 (−0.2 to 0.1) | 0.73 | −0.6 (−0.8 to −0.4) | <0.001 | <0.001 |
Posterior wall thickness (cm/BSA0.4) | 0.02 (−0.03 to 0.08) | 0.38 | 0.04 (−0.03 to 0.10) | 0.26 | 0.72 |
LV mass (g/BSA1.25) | 4.0 (−5.2 to 13.2) | 0.39 | −7.1 (−18.8 to 4.6) | 0.23 | 0.11 |
Relative wall thickness | 0.00 (−0.03 to 0.03) | 0.91 | 0.05 (0.01 to 0.08) | 0.015 | 0.046 |
Circumferential strain (%)§ | −3.4 (−6.8 to 0.0) | 0.049 | −0.6 (−5.0 to 3.8) | 0.78 | 0.27 |
Radial strain (%) | 4.6 (−8.2 to 17.5) | 0.47 | 9.9 (−6.9 to 26.8) | 0.24 | 0.58 |
Meridional ESS (103 dynes/cm2) | −7.9 (−24.0 to 8.2) | 0.33 | −29.2 (−51.1 to −7.2) | 0.010 | 0.089 |
Circumferential ESS (103 dynes/cm2) | −7.1 (−23.6 to 9.3) | 0.39 | −18.9 (−41.6 to 3.9) | 0.10 | 0.36 |
*Difference in the mean change at T1 (within 6 months of doxorubicin therapy completion) between subjects who were exposed and not exposed to dexrazoxane, derived from propensity-adjusted multivariable linear regression.
†P<0.05 for the comparison of mean changes by dexrazoxane exposure, performed separately for males and females.
‡P-values for the interaction between sex and dexrazoxane.
§Increases reflect deterioration of circumferential strain.
LVIDS, LV inner dimension in systole
BSA, body surface area;ESS, end-systolic stress;LV, left ventricular;LVIDD, LV inner dimension in diastole.